Kessler Topaz Meltzer & Check, LLP Announces Expanded Investigation of Theranos, Inc. on Behalf of Investors

RADNOR, PA / ACCESSWIRE / January 28, 2016 / The law firm of Kessler Topaz Meltzer & Check, LLP announces an expanded investigation of Theranos, Inc. (“Theranos” or the “Company”) on behalf of the Company’s investors.

Theranos investors who wish to discuss this investigation and/or their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or at info@ktmc.com. For additional information about this investigation, or to request information about this investigation online, please visit www.ktmc.com/theranos-inc.

On October 16, 2015, The Wall Street Journal reported that investors have “poured more than $400 million into Theranos,” valuing the Company at $9 billion, but that Theranos “has struggled behind the scenes to turn the excitement over its technology into reality.” Further, The Wall Street Journal reported that due to questions raised by the FDA, the Company had “temporarily halted its trademark practice of collecting tiny blood samples from finger pricks.”

On December 27, 2015, The Wall Street Journal reported that, shortly after passing a critical inspection by the Centers for Medicare and Medicaid Services (“CMS”) in which the agency looked at the Company’s lab instruments, Theranos raised $633 million from investors. According to Business Insider, that inspection “did not examine the ‘revolutionary’ technology that aims to run its tests on only a finger-prick’s worth of blood. Instead, the inspectors only looked at the tests that were run using traditional lab equipment.”

Most recently, on January 27, 2016, The Wall Street Journal reported that “Federal inspectors found ‘deficient practices’ at a Theranos Inc. laboratory that ‘pose immediate jeopardy to patient health and safety.'” The article further reported that a CMS inspection had “uncovered five major infractions that violate the federal law governing clinical labs,” and that one infraction was defined “as a situation ‘likely to cause, at any time, serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.'”

Theranos investors who wish to discuss this investigation and/or their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or at info@ktmc.com. For additional information about this investigation, or to request information about this investigation online, please visit www.ktmc.com/theranos-inc.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299 – 7706
(610) 667 – 7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 436132